Your Web Site
News source: Business Wire In a European biotech investment environment under pressure, fast-growing Danish biotech company Fluxome Sciences A/S announces a capital increase of DKK 100 mio/EUR 13 mio. The DKK 100 mio/EUR 13 mio capital increase has been secured through a continued strong commitment from current investors SEVENTURE Partners (France), INCUBA Venture (Denmark), VECATA A/S (Denmark) and the addition of one of Europe's leading cleantech funds, Capricorn Cleantech Fund, managed by CAPRICORN Venture Partners (Belgium), to the group of share holders. "I am very satisfied with the strengthening of our capital foundation and panel of investors", Chairman of the Board of Fluxome Sciences, Erik Hojsholt says. "The capital increase of DKK 100 mio will provide the capital needed to continue the execution of Fluxome's... [read full story]
